Gufic Biosciences promoted two senior executives to key leadership positions effective September 2, 2026. The board approved the changes following a recommendation from the Nomination & Remuneration Committee.

Ms. Ami Shah was promoted to Head-Legal while retaining her role as Company Secretary & Compliance Officer. Mr. Pinak Padhya was elevated from Vice President to President – Sales & Marketing.

Regulatory Disclosure

The company issued an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This disclosure complies with Part A of Schedule III of the Listing Regulations.

Executive Profiles

Ms. Shah holds a law degree (LL.B.) and is a qualified Company Secretary. She has served Gufic Biosciences for over 10 years. Her responsibilities include corporate governance, statutory compliance, and managing intellectual property matters.

Mr. Padhya brings over 28 years of experience in the pharmaceutical industry. He holds an MBA in Marketing and a Pharmacy Graduate degree. His previous roles include positions at Sun Pharma, Ranbaxy, Glenmark, Elder, Medley, and Cadila Pharma.

Key Responsibilities

Ms. Shah continues to serve as a Key Managerial Personnel. Her background includes drafting commercial agreements and handling litigation. She previously worked with the JM Baxi Group as Senior Executive – Secretarial Team.

Mr. Padhya’s expertise covers multiple therapeutic areas including Orthopaedics, Gastrointestinal, Gynaecology, Herbal, Dermatology, Pediatrics, and General Practice. He focuses on strategic brand building and cluster growth.

Gufic BioSciences Limited has made available the written transcript of its earnings conference call held on August 17, 2026. The document, filed with stock exchanges on August 21, 2026, details the company's financial performance and strategic updates for the first quarter of FY27.

The disclosure was issued pursuant to Regulation 30 read with Part A of Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This filing supersedes the earlier intimation regarding the audio recording of the same event.

Ami Shah, Company Secretary and Compliance Officer, signed the communication on behalf of the management.

Financial Performance Highlights

During the call, management provided a comparative overview of Q1FY27 results against the previous year and quarter. Revenue from operations grew to ₹260.8 crore in Q1FY27, up from ₹226.9 crore in Q1FY26. EBITDA expanded to ₹47.2 crore, reflecting an improvement in margins.

Profit after tax (PAT) rose to ₹22.46 crore in Q1FY27, compared to ₹12.1 crore in the same period last year. The PAT margin improved to 8.61% from 5.3% in Q1FY26.